Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Preferred Stock Liabilities: 2013-2016

  • Soleno Therapeutics' Preferred Stock Liabilities rose 160.00% to $13 in Q4 2016 from the same period last year, while for Dec 2016 it was $13, marking a year-over-year increase of 160.00%. This contributed to the annual value of $13 for FY2016, which is 160.00% up from last year.
  • Latest data reveals that Soleno Therapeutics reported Preferred Stock Liabilities of $13 as of Q4 2016, which was up 160.00% from $5 recorded in Q4 2015.
  • Over the past 5 years, Soleno Therapeutics' Preferred Stock Liabilities peaked at $15.4 million during Q4 2013, and registered a low of $5 during Q4 2015.
  • For the 3-year period, Soleno Therapeutics' Preferred Stock Liabilities averaged around $5.1 million, with its median value being $13 (2016).
  • Data for Soleno Therapeutics' Preferred Stock Liabilities shows a peak YoY spiked of 160.00% (in 2016) over the last 5 years.
  • Soleno Therapeutics' Preferred Stock Liabilities (Quarterly) stood at $15.4 million in 2013, then reached $15.4 million in 2014, then reached $5 in 2015, then spiked by 160.00% to $13 in 2016.
  • Its Preferred Stock Liabilities stands at $13 for Q4 2016, versus $5 for Q4 2015 and $15.4 million for Q3 2014.